If this is confirmed by future studies, clinical implication will be that long-term treatment with IGF-1 or its agonists may be beneficial in cases where brain injury carries relatively low risk of epilepsy, but harmful in cases where epilepsy risk is high. Here, IGF1 is linked to epilepsy.